SXTP
- 60 Degrees Pharmaceuticals, Inc.
()
Overview
Company Summary
60 Degrees Pharmaceuticals, Inc. (SXTP) is a pharmaceutical company that focuses on developing and providing innovative solutions for the prevention and treatment of tropical and neglected diseases.
The company's primary goal is to address the unmet medical needs of people living in regions affected by these diseases, particularly in resource-limited settings. They aim to tackle both the prevalence and impact of tropical diseases, such as malaria, cholera, dengue fever, and others.
60 Degrees Pharmaceuticals, Inc. conducts extensive research and development to create new drugs and treatments that are effective, safe, and affordable for the affected populations. They work closely with global health organizations, governments, and research institutions to develop partnerships and ensure the distribution of their products to those who need them the most.
One of the company's notable accomplishments is the development of Tafenoquine, an anti-malarial drug approved by the U.S. Food and Drug Administration (FDA) in 2018. Tafenoquine provides a single-dose treatment option for relapsing malaria, reducing the burden on patients and healthcare systems.
In addition to research and development, 60 Degrees Pharmaceuticals, Inc. is involved in activities related to regulatory approval, manufacturing, supply chain management, and distribution of their products. Their focus extends beyond developing drugs, as they employ a holistic approach to improve healthcare systems and access to treatment in affected regions.
Overall, 60 Degrees Pharmaceuticals, Inc. is dedicated to advancing the prevention and treatment of tropical and neglected diseases by developing innovative pharmaceutical solutions and collaborating with various stakeholders to ensure widespread access to these treatments.